Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran PK Interaction with Famotidine
NCT04941755Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of afimetoran in systemic lupus erythematosus (SLE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 19 days, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration up to 19 days and 1 more. Started Jun 2021; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04941755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941755.